STOCK TITAN

Edgewise Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Edgewise Therapeutics (NASDAQ: EWTX) announced its participation in the J.P. Morgan 41st Annual Healthcare Conference on January 10, 2023, at 9:45 am PT (12:45 pm ET). The presentation will be available via a live webcast, with a replay option post-event. Edgewise focuses on developing targeted therapies for severe muscle disorders, including its lead candidate, EDG-5506, aimed at treating Duchenne muscular dystrophy. The company is advancing another candidate, EDG-7500, for hypertrophic cardiomyopathy in preclinical development.

Positive
  • None.
Negative
  • None.

BOULDER, Colo.--(BUSINESS WIRE)-- Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, targeted, small molecule therapies for the treatment of devastating muscle disorders, today announced that management will present at the J.P. Morgan 41st Annual Healthcare Conference on Tuesday, January 10, 2023, at 9:45 am PT (12:45 pm ET).

The presentation will be webcast live; a link for the webcast can be found on the Edgewise events page and will be accessible for replay following the presentation. It is recommended that users connect to the webcast several minutes prior to the start to ensure a timely connection.

About Edgewise Therapeutics

Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative treatments for severe, rare neuromuscular and cardiac disorders for which there is significant unmet medical need. Guided by its holistic drug discovery approach to targeting the muscle as an organ, Edgewise has combined its foundational expertise in muscle biology and small molecule engineering to build its proprietary, muscle-focused drug discovery platform. Edgewise’s platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue. The Company’s lead candidate, EDG-5506, an investigational orally administered small molecule myosin modulator designed to protect injury-susceptible fast skeletal muscle fibers in dystrophinopathies, is advancing in multiple clinical trials in individuals with Duchenne muscular dystrophy or Becker muscular dystrophy. The Company is also advancing EDG-7500, a novel sarcomere modulator for hypertrophic cardiomyopathy, into IND-enabling preclinical development. To learn more, go to: www.edgewisetx.com or follow us on LinkedIn, Twitter and Facebook.

Investors & Media

Michael Carruthers

Chief Financial Officer

ir@edgewisetx.com

Source: Edgewise Therapeutics

FAQ

When will Edgewise Therapeutics present at the J.P. Morgan 41st Annual Healthcare Conference?

Edgewise Therapeutics will present on January 10, 2023, at 9:45 am PT (12:45 pm ET).

What is the focus of Edgewise Therapeutics?

Edgewise Therapeutics focuses on developing targeted therapies for severe muscle disorders.

What candidates is Edgewise Therapeutics developing?

Edgewise is developing EDG-5506 for Duchenne muscular dystrophy and EDG-7500 for hypertrophic cardiomyopathy.

Where can I find the webcast for Edgewise Therapeutics' presentation?

The webcast link for Edgewise's presentation can be found on their events page, linked in their press release.

Edgewise Therapeutics, Inc.

NASDAQ:EWTX

EWTX Rankings

EWTX Latest News

EWTX Stock Data

3.00B
73.99M
0.47%
111.61%
6.75%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
BOULDER